Alotamide A, a novel neuropharmacological agent from the marine cyanobacterium Lyngbya bouillonii

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Cyanobacteria are a diverse group of oxygenic, phototrophic bacteria that played a pivotal role in converting Earth’s atmosphere from anoxic to oxygen-rich billions of years ago. They exhibit remarkable morphological diversity, ranging from unicellular forms to filamentous types, with cell sizes varying between 0.5 μm and 100 μm. Cyanobacteria are classified into five groups: Chroococcales (unicellular, dividing by binary fission), Pleurocapsales (unicellular, dividing by multiple fission),...

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...